Pharmaceutical Product Catalog

Effective January 1, 2019, VIEKIRA XR and TECHNIVIE will no longer be available in the U.S.A. Until January 1, 2019, supply of these medications will be available for all patients who begin therapy prior to July 1, 2018, to ensure that they are able to obtain product necessary to complete their course of prescribed therapy. Accordingly, AbbVie advises that physicians should cease writing any new prescriptions for VIEKIRA XR and TECHNIVIE effective July 1, 2018.

nav nav
VIEKIRA PAK 12.5/75/50/250MG TABS, 28DAY
NDC number: 00074309328
Product Family: VIEKIRA
Dosage Form: TAB
Strength: Announcement Below
Imprint: AV1;AV2
Approval Date: 12/19/2014
Controlled Substance: RX
Therapeutic Class:
ANTIVIRAL (HCV direct acting antiviral)
List Price: $999,999.00
List Effective Date: 10/10/2014
WAC Price: $999,999.00
WAC Effective Date: 10/10/2014
Product Dimensions
Each Length (in): 5.25
Each Width (in): 7.88
Each Height (in): 5.25
Packaging Details
Packaging Information
Unit Of Measure: BOX
Inner Pack:
Quantity / Salable Unit: 112 TABS (56 + 56)
Case Size: 4
Total Cases / Pallet: 72
Total Pallet Weight (lbs): 617.04
Number of Tiers:
Cases / Tier:
Case Details
Case Weight (lbs): 8.57
Case Volume (cu ft): 1164.16
Length (in) Width (in) Height (in)
Outer Case 11.38 16.38 6.25
Inner Case
56 / 12.5mg/75mg/50mg ombitasvir/paritaprevir/ritonavir tablets & 56 /250mg dasabuvir tablets
Additional Information
Product and pricing detail may change. Please return to www.e-abbvie.com for the current product and pricing information.
Copyright © Abbvie Version 2.5